June 2025 - Page 13 of 16

FridayJun 06, 2025 9:35 am

QualityStocksNewsBreaks – Authentic Holdings (OTC: AHRO) Subsidiary Maybacks Signs Streaming Deal With Plex

Authentic Holdings (OTC: AHRO) announced that its wholly owned subsidiary, Maybacks Global Entertainment, LLC, has entered into a licensing and distribution agreement with Plex GmbH to bring its iDreamCTV network brands—Toro TV, Comfy TV, Winnie’s World, and iCowboy—to a global streaming audience. The partnership leverages Plex’s AVOD and FAST channel infrastructure to monetize and distribute Maybacks’ content across its 25 million-user platform. Following its acquisition of Goliath Motion Picture Promotions, Maybacks is pivoting from traditional film sales to building proprietary media brands with scalable digital reach. To view the full press release, visit https://ibn.fm/hnCSv About Authentic Holdings Authentic Holdings combines…

ThursdayJun 05, 2025 1:38 pm

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Unveils Promising Data on CLD-401 at ASCO 2025

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads. The company unveiled promising new data on its lead RedTail platform candidate, CLD-401, at the American Society of Clinical Oncology (“ASCO”) Annual Meeting. The announcement reads, “Calidi has previously demonstrated its pioneering efforts in developing an enveloped form of its proprietary oncolytic virus that is significantly more resistant to immune clearance than non-enveloped forms, allowing for systemic delivery and efficacy in syngeneic tumor-bearing pre-clinical models. Calidi has further advanced this technology with CLD-401, its first…

ThursdayJun 05, 2025 11:15 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a planned national clinic network, and is expected to immediately improve revenue and EBITDA for NRx and HOPE Therapeutics. HOPE aims to develop a network of up to 30 interventional psychiatry clinics by the end of 2025, with a $100 million pro forma run rate by YE 25. Kadima specializes in interventional psychiatry, and Kadima’s founder Dr. David Feifel, will join HOPE as Chief Medical Innovation Officer. NRx’s broader pipeline includes FDA-designated treatments for bipolar depression and acute suicidality. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical…

ThursdayJun 05, 2025 10:30 am

Nightfood Holdings Inc. (NGTF) Taps Proven Leaders to Accelerate Hospitality Innovation

Nightfood Holdings new executives have strong track records in a variety of spaces NGTF's new leadership team is poised to leverage their combined expertise to facilitate the company's growth and innovation The foundation of any successful company often rests on the quality and vision of its leadership. Experienced executives can be the deciding factor between stagnation and rapid growth, particularly in dynamic sectors such as consumer goods and hospitality. That’s why Nightfood Holdings (OTCQB: NGTF) made waves recently with its announcement of new senior leadership appointments aimed at accelerating innovation and expansion across its growing portfolio of hospitality-focused services. According…

ThursdayJun 05, 2025 10:00 am

QualityStocksNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Italian Clearance for Option to Acquire Biotech Firm Pincell

Scinai Immunotherapeutics (NASDAQ: SCNI) announced it has received regulatory clearance under Italy’s Golden Power regulation to proceed with its option to acquire 100% of Pincell S.r.l., an Italian biotech company. The approval, issued by Italy’s Coordination Group and Ministry of Health, supports Scinai’s strategic move to expand its inflammation and immunology pipeline. Pincell’s lead asset, PC111—a monoclonal antibody targeting the Fas/FasL pathway—holds Orphan Drug Designation in Pemphigus and is being developed for severe skin disorders. The acquisition remains subject to final conditions, including a €12 million grant decision expected later this summer. To view the full press release, visit https://ibn.fm/qoRQ1…

ThursdayJun 05, 2025 9:50 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit

CNS Pharmaceuticals (NASDAQ: CNSP) announced that Chief Medical Officer Sandra Silberman, M.D., Ph.D., will present at the Brain Tumor Biotech Summit hosted by Lenox Hill Hospital’s Department of Neurosurgery on June 5, 2025. Her presentation, titled "The Future and Promise of TPI 287," will highlight CNS’s brain-penetrating taxane candidate, which has shown efficacy in glioblastoma patients, including 3 complete and 9 partial responses in a Phase 1 trial. TPI 287, which has FDA Orphan Drug Designation for gliomas, pediatric neuroblastoma, and progressive supranuclear palsy, may offer a breakthrough in treating CNS tumors by effectively crossing the blood-brain barrier. To view…

ThursdayJun 05, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology

Buprenorphine is a medication approved by the U.S. Food and Drug Administration (“FDA”) to treat opioid use disorder and chronic and severe pain Nutriband is developing a novel transdermal delivery system for buprenorphine, projected to reach peak annual sales of $70M - $130M The company’s AVERSA pipeline currently includes two main candidates: AVERSA(TM) Fentanyl and AVERSA(TM) Buprenorphine As the opioid epidemic continues to pose one of the most critical public health crises in the United States and around the world, the need for innovative, safer treatments has never been more urgent. One company, Nutriband (NASDAQ: NTRB), is aiming to transform how opioid-based therapies are administered and protected…

ThursdayJun 05, 2025 9:30 am

QualityStocksNewsBreaks – Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Reports Promising Copper Targets at Epworth Project in Nunavut

Aston Bay (TSX.V: BAY) (OTCQB: ATBHF) has released results from its 2024 exploration program at the Epworth Project in Nunavut, highlighting surface samples with copper grades up to 61.2% and silver up to 5,600 g/t. The company’s MobileMT airborne geophysical survey identified extensive conductive bodies—interpreted as potential reductants such as pyrite or graphite—within the Proterozoic Recluse Group rocks. CEO Thomas Ullrich stated these findings support the potential for a large-scale, sediment-hosted copper system, drawing parallels to successful models used in Central Africa and Aston Bay’s Storm Copper Project. Targets span tens of kilometers and are largely within 300 meters of…

ThursdayJun 05, 2025 9:20 am

QualityStocksNewsBreaks – SolarBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) to Allocate Solar Project Revenue to Bitcoin Treasury Strategy

Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) has taken its first step toward implementing a Bitcoin treasury strategy by committing net revenue from its 3.79 MW Geddes Solar Power Project to Bitcoin purchases. This initiative places SolarBank among the early renewable energy companies integrating digital assets into corporate finance. The Geddes Project, built on a repurposed landfill, is expected to begin operations by the end of June 2025. CEO Dr. Richard Lu described the move as a strategic blend of stable energy cash flow and Bitcoin’s appreciation potential, with future expansions of the…

ThursdayJun 05, 2025 9:00 am

QualityStocksNewsBreaks – ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Featured in Editorial Highlighting Next Wave of Scalable Gold Producers

ESGold (CSE: ESAU) (OTCQB: ESAUF) today announced its inclusion in a NetworkNewsWire (“NNW”) editorial spotlighting the emerging class of near-term gold producers positioned for institutional interest. As gold prices climbed above $3,000 per ounce in May 2025, investor demand has shifted toward companies offering leverage, scalability and recurring revenue—traits ESGold is designed to deliver. With a clean balance sheet and scalable model, ESGold is gaining attention as central banks increase gold reserves and institutional capital seeks stronger exposure to the metal’s long-term upside. To view the full press release, visit https://ibn.fm/vbgsS About ESGold Corp. ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) (FSE: Z7D) is…

Site Search

Company Search

Month: June 2025